## Victor H Engelhard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3229106/publications.pdf

Version: 2024-02-01

all docs

32410 39744 10,321 128 55 98 citations h-index g-index papers 139 139 139 10051 docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. Cancer Cell, 2022, 40, 524-544.e5.	7.7	23
2	Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. Cancer Immunology Research, 2021, 9, 583-597.	1.6	9
3	Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma., 2021, 9, e002273.		39
4	Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Reports, 2021, 36, 109422.	2.9	89
5	Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates. Journal of Translational Medicine, 2021, 19, 371.	1.8	9
6	Phospho- $\hat{l}^2$ -catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2. Pathology Research and Practice, 2021, 224, 153527.	1.0	2
7	Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients. Cancer Immunology Research, 2021, 9, 1327-1341.	1.6	4
8	Antibiotics Drive Microbial Imbalance and Vitiligo Development in Mice. Journal of Investigative Dermatology, 2020, 140, 676-687.e6.	0.3	38
9	Immunomodulation of intracranial melanoma in response to blood-tumor barrier opening with focused ultrasound. Theranostics, 2020, 10, 8821-8833.	4.6	25
10	Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy. Cancer Immunology Research, 2020, 8, 1338-1345.	1.6	44
11	MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma., 2020, 8, e000262.		44
12	Abstract B68: Pre-existing immune memory to cancer-associated phosphopeptides in healthy donors. , 2020, , .		0
13	Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors. Cancer Immunology, Immunotherapy, 2019, 68, 1121-1132.	2.0	13
14	The Antigen Processing and Presentation Machinery in Lymphatic Endothelial Cells. Frontiers in Immunology, 2019, 10, 1033.	2.2	70
15	Comparative Transcriptomic Analysis Identifies a Range of Immunologically Related Functional Elaborations of Lymph Node Associated Lymphatic and Blood Endothelial Cells. Frontiers in Immunology, 2019, 10, 816.	2.2	35
16	The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis. Annals of Surgery, 2019, 270, 712-722.	2.1	14
17	Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. Journal of Immunology, 2018, 200, 432-442.	0.4	153
18	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. Oncolmmunology, 2018, 7, e1490855.	2.1	10

#	Article	IF	CITATIONS
19	Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods in Molecular Biology, 2018, 1845, 241-257.	0.4	18
20	Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. Journal of Clinical Investigation, 2018, 128, 1338-1354.	3.9	64
21	Differential Expression of Homing Receptor Ligands on Tumor-Associated Vasculature that Control CD8 Effector T-cell Entry. Cancer Immunology Research, 2017, 5, 1062-1073.	1.6	29
22	Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma. Journal of Proteome Research, 2017, 16, 228-237.	1.8	34
23	The antigenic identity of human class I MHC phosphopeptides is critically dependent upon phosphorylation status. Oncotarget, 2017, 8, 54160-54172.	0.8	42
24	Abstract 4609: Agenus' next generation cancer vaccine platforms. , 2017, , .		0
25	Effect of cancer vaccine formulation on synergy with anti-CTLA-4 and anti-PD-L1 checkpoint blockade therapy of cancer Journal of Clinical Oncology, 2016, 34, 3094-3094.	0.8	0
26	Abstract A031: Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. , 2016, , .		0
27	Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Advances in Cancer Research, 2015, 128, 263-307.	1.9	123
28	Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nature Communications, 2015, 6, 7114.	5.8	139
29	Roles of lymphatic endothelial cells expressing peripheral tissue antigens in CD4 T-cell tolerance induction. Nature Communications, 2015, 6, 6771.	5.8	138
30	Abstract IA23: T cell trafficking in lymphoid and non-lymphoid tissues. , 2015, , .		0
31	Regulation of T-cell Tolerance by Lymphatic Endothelial Cells. Journal of Clinical & Cellular Immunology, 2014, 05, .	1.5	40
32	Immune responses in a mouse model of vitiligo with spontaneous epidermal de―and repigmentation. Pigment Cell and Melanoma Research, 2014, 27, 1075-1085.	1.5	27
33	MHC-Restricted Phosphopeptides from Insulin Receptor Substrate-2 and CDC25b Offer Broad-Based Immunotherapeutic Agents for Cancer. Cancer Research, 2014, 74, 6784-6795.	0.4	28
34	Tolerogenic Properties of Lymphatic Endothelial Cells Are Controlled by the Lymph Node Microenvironment. PLoS ONE, 2014, 9, e87740.	1.1	95
35	MHC Class I–Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia. Science Translational Medicine, 2013, 5, 203ra125.	5.8	186
36	Peripheral Tissue Homing Receptors Enable T Cell Entry into Lymph Nodes and Affect the Anatomical Distribution of Memory Cells. Journal of Immunology, 2013, 191, 2412-2425.	0.4	25

#	Article	IF	Citations
37	Regulatory T cells and vasectomy. Journal of Reproductive Immunology, 2013, 100, 66-75.	0.8	28
38	Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity. Cancer Cell, 2013, 23, 516-526.	7.7	131
39	Peripheral Tissue Homing Receptor Control of Na $ ilde{A}$ -ve, Effector, and Memory CD8 T Cell Localization in Lymphoid and Non-Lymphoid Tissues. Frontiers in Immunology, 2013, 4, 241.	2.2	42
40	Lymphatic endothelial cells - key players in regulation of tolerance and immunity. Frontiers in Immunology, 2012, 3, 305.	2.2	66
41	Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood, 2012, 120, 4772-4782.	0.6	256
42	Abstract 512: Leukemia-specific immunity in healthy individuals and patients post-transplant targets phosphorylated tumor antigens. , 2012, , .		0
43	Abstract 1584: MHC-restricted phosphopeptides as broad-based immunotherapeutic targets for cancer. , 2012, , .		0
44	Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. Journal of Experimental Medicine, 2010, 207, 1791-1804.	4.2	211
45	CD8 T Cells Activated in Distinct Lymphoid Organs Differentially Express Adhesion Proteins and Coexpress Multiple Chemokine Receptors. Journal of Immunology, 2010, 184, 4079-4086.	0.4	55
46	Lymph node–resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. Journal of Experimental Medicine, 2010, 207, 681-688.	4.2	321
47	Mechanisms of Spatial and Temporal Development of Autoimmune Vitiligo in Tyrosinase-Specific TCR Transgenic Mice. Journal of Immunology, 2010, 184, 1909-1917.	0.4	100
48	Targeting allergen to $Fc\hat{l}^3RI$ reveals a novel TH2 regulatory pathway linked to thymic stromal lymphopoietin receptor. Journal of Allergy and Clinical Immunology, 2010, 125, 247-256.e8.	1.5	36
49	Structural Basis for the Presentation of Tumor-Associated MHC Class II-Restricted Phosphopeptides to CD4+ T Cells. Journal of Molecular Biology, 2010, 399, 596-603.	2.0	37
50	Abstract B14: A phosphorylated $\hat{l}^2$ -catenin peptide that is presented by HLA-A2 MHC molecules generates strong phosphospecific T cell responses against melanoma. , 2010, , .		0
51	Immunologically Targeting the Leukaemia Phosphoproteome. Blood, 2010, 116, 1016-1016.	0.6	O
52	Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12073-12078.	3.3	98
53	N-Glycosylation Enhances Presentation of a MHC Class I-Restricted Epitope from Tyrosinase. Journal of Immunology, 2009, 182, 4830-4835.	0.4	28
54	Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3889-3894.	3.3	36

#	Article	IF	CITATIONS
55	Strategies and challenges in eliciting immunity to melanoma. Immunological Reviews, 2008, 222, 28-42.	2.8	19
56	Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nature Immunology, 2008, 9, 1236-1243.	7.0	130
57	Targeting Fel d $1$ to Fc $\hat{l}^3$ RI induces a novel variation of the TH2 response in subjects with cat allergy. Journal of Allergy and Clinical Immunology, 2008, 121, 756-762.e4.	1.5	25
58	Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases. Journal of Immunology, 2008, 180, 130-137.	0.4	55
59	Activated CD8 T Cells Redistribute to Antigen-Free Lymph Nodes and Exhibit Effector and Memory Characteristics. Journal of Immunology, 2008, 181, 1814-1824.	0.4	17
60	MHC Class II Presentation of gp100 Epitopes in Melanoma Cells Requires the Function of Conventional Endosomes and Is Influenced by Melanosomes. Journal of Immunology, 2008, 181, 7843-7852.	0.4	39
61	Tumorâ€nssociated MHC IIâ€restricted phosphopeptides: New targets for immune recognition. FASEB Journal, 2008, 22, 1079.1.	0.2	1
62	NKT Cell Activation Mediates Neutrophil IFN- $\hat{I}$ 3 Production and Renal Ischemia-Reperfusion Injury. Journal of Immunology, 2007, 178, 5899-5911.	0.4	307
63	Dendritic Cell Immunization Route Determines Integrin Expression and Lymphoid and Nonlymphoid Tissue Distribution of CD8 T Cells. Journal of Immunology, 2007, 178, 1512-1522.	0.4	30
64	Deletional Self-Tolerance to a Melanocyte/Melanoma Antigen Derived from Tyrosinase Is Mediated by a Radio-Resistant Cell in Peripheral and Mesenteric Lymph Nodes. Journal of Immunology, 2007, 179, 993-1003.	0.4	132
65	The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes. International Journal of Mass Spectrometry, 2007, 259, 32-39.	0.7	20
66	Immune Targeting of the Phosphoproteome in Lymphoma and Leukemia Blood, 2007, 110, 285-285.	0.6	1
67	Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. Journal of Experimental Medicine, 2006, 203, 2639-2648.	4.2	271
68	The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood, 2006, 107, 3779-3786.	0.6	99
69	Post-translational modifications of naturally processed MHC-binding epitopes. Current Opinion in Immunology, 2006, 18, 92-97.	2.4	109
70	Immunity to Melanoma Antigens: From Selfâ€Tolerance to Immunotherapy. Advances in Immunology, 2006, 90, 243-295.	1,1	55
71	Peptide and Dendritic Cell Vaccines. Clinical Cancer Research, 2006, 12, 2342s-2345s.	3.2	30
72	Limited Infiltration of Exogenous Dendritic Cells and Naive T Cells Restricts Immune Responses in Peripheral Lymph Nodes. Journal of Immunology, 2006, 176, 4535-4542.	0.4	19

#	Article	IF	Citations
73	Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14889-14894.	3.3	168
74	Processing of a Class I-Restricted Epitope from Tyrosinase Requires Peptide N-Glycanase and the Cooperative Action of Endoplasmic Reticulum Aminopeptidase 1 and Cytosolic Proteases. Journal of Immunology, 2006, 177, 5440-5450.	0.4	40
75	Incomplete Differentiation of Antigen-Specific CD8 T Cells in Tumor-Draining Lymph Nodes. Journal of Immunology, 2006, 177, 6081-6090.	0.4	55
76	Adenosine A2Areceptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. Journal of Cell Biology, 2006, 175, i9-i9.	2.3	1
77	Sphingosine Kinase 2 Is Required for Modulation of Lymphocyte Traffic by FTY720. Journal of Biological Chemistry, 2005, 280, 36865-36872.	1.6	198
78	Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma. Journal of Immunology, 2005, 174, 6863-6871.	0.4	91
79	Regulated Folding of Tyrosinase in the Endoplasmic Reticulum Demonstrates That Misfolded Full-Length Proteins Are Efficient Substrates for Class I Processing and Presentation. Journal of Immunology, 2005, 174, 2544-2551.	0.4	39
80	Identification of Novel and Widely Expressed Cancer/Testis Gene Isoforms That Elicit Spontaneous Cytotoxic T-Lymphocyte Reactivity to Melanoma. Cancer Research, 2004, 64, 1157-1163.	0.4	21
81	Creating new peptide antigens by slicing and splicing proteins. Nature Immunology, 2004, 5, 128-129.	7.0	6
82	Preventing the Spontaneous Modification of an HLA-A2-Restricted Peptide at an N-Terminal Glutamine or an Internal Cysteine Residue Enhances Peptide Antigenicity. Journal of Immunotherapy, 2004, 27, 177-183.	1.2	9
83	Competition Among Peptides in Melanoma Vaccines for Binding to MHC Molecules. Journal of Immunotherapy, 2004, 27, 425-431.	1.2	14
84	Identification of a shared epitope recognized by melanoma-specific, HLA-A3-restricted cytotoxic T lymphocytes. Immunology Letters, 2003, 90, 131-135.	1.1	11
85	Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus -host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. British Journal of Haematology, 2003, 123, 671-675.	1.2	49
86	Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells. Journal of Clinical Oncology, 2003, 21, 4016-4026.	0.8	303
87	Tapasin Is a Facilitator, Not an Editor, of Class I MHC Peptide Binding. Journal of Immunology, 2003, 171, 5287-5295.	0.4	103
88	Antigen Density Presented By Dendritic Cells In Vivo Differentially Affects the Number and Avidity of Primary, Memory, and Recall CD8+ T Cells. Journal of Immunology, 2003, 170, 1822-1829.	0.4	116
89	Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control. Journal of Experimental Medicine, 2003, 198, 1023-1034.	4.2	196
90	The minor histocompatibility antigen HA-3 arises from differential proteasome–mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood, 2003, 102, 621-629.	0.6	118

#	Article	IF	CITATIONS
91	Analysis of MHC Class II Antigen Processing by Quantitation of Peptides that Constitute Nested Sets. Journal of Immunology, 2002, 169, 5089-5097.	0.4	88
92	Identification by Mass Spectrometry of CD8+-T-Cell Mycobacterium tuberculosis Epitopes within the Rv0341 Gene Product. Infection and Immunity, 2002, 70, 2926-2932.	1.0	43
93	Insights into antigen processing gained by direct analysis of the naturally processed class I MHC associated peptide repertoire. Molecular Immunology, 2002, 39, 127-137.	1.0	61
94	Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study. International Journal of Cancer, 2002, 98, 221-227.	2.3	28
95	Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunological Reviews, 2002, 188, 136-146.	2.8	117
96	Tyrosinase Degradation via Two Pathways during Reverse Translocation to the Cytosol. Biochemical and Biophysical Research Communications, 2001, 285, 313-319.	1.0	20
97	Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. International Journal of Cancer, 2001, 92, 703-711.	2.3	114
98	Determination of Intronic Sequences Adjacent to an Exon Using Polymerase Chain Reaction and Genomic DNA Library Constructed by TA Cloning. Analytical Biochemistry, 2001, 289, 289-292.	1.1	1
99	The Immunogenicity of a New Human Minor Histocompatibility Antigen Results from Differential Antigen Processing. Journal of Experimental Medicine, 2001, 193, 195-206.	4.2	191
100	The HA-2 Minor Histocompatibility Antigen Is Derived from a Diallelic Gene Encoding a Novel Human Class I Myosin Protein. Journal of Immunology, 2001, 167, 3223-3230.	0.4	125
101	Manipulation of Avidity to Improve Effectiveness of Adoptively Transferred CD8+ T Cells for Melanoma Immunotherapy in Human MHC Class I-Transgenic Mice. Journal of Immunology, 2001, 167, 5824-5831.	0.4	79
102	Differences in the Expression of Human Class I MHC Alleles and Their Associated Peptides in the Presence of Proteasome Inhibitors. Journal of Immunology, 2001, 167, 1212-1221.	0.4	77
103	Immune Responses to the HLA-A*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice. Journal of Immunology, 2001, 167, 4853-4860.	0.4	48
104	Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients., 2001, 92, 703.		1
105	Pseudomonas Exotoxin-Mediated Delivery of Exogenous Antigens to MHC Class I and Class II Processing Pathways. Cellular Immunology, 2000, 203, 75-83.	1.4	18
106	Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. Cancer Immunology, Immunotherapy, 2000, 48, 661-672.	2.0	89
107	Immunodominance Among EBV-Derived Epitopes Restricted by HLA-B27 Does Not Correlate with Epitope Abundance in EBV-Transformed B-Lymphoblastoid Cell Lines. Journal of Immunology, 2000, 164, 6120-6129.	0.4	73
108	The Density of Peptides Displayed by Dendritic Cells Affects Immune Responses to Human Tyrosinase and gp100 in HLA-A2 Transgenic Mice. Journal of Immunology, 2000, 164, 2354-2361.	0.4	92

#	Article	IF	Citations
109	Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen. Journal of Experimental Medicine, 2000, 191, 1221-1232.	4.2	154
110	Phosphorylated Peptides Are Naturally Processed and Presented by Major Histocompatibility Complex Class I Molecules in Vivo. Journal of Experimental Medicine, 2000, 192, 1755-1762.	4.2	192
111	Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100., 1999, 82, 669-677.		77
112	Terminal modifications inhibit proteolytic degradation of an immunogenic mart-127-35 peptide: Implications for peptide vaccines., 1999, 83, 326-334.		152
113	The Minor Histocompatibility Antigen HA-1: A Diallelic Gene with a Single Amino Acid Polymorphism. Science, 1998, 279, 1054-1057.	6.0	399
114	The Class I Antigen-processing Pathway for the Membrane Protein Tyrosinase Involves Translation in the Endoplasmic Reticulum and Processing in the Cytosol. Journal of Experimental Medicine, 1998, 187, 37-48.	4.2	109
115	The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68. Journal of Experimental Medicine, 1997, 185, 695-706.	4.2	125
116	The HLA-A*0201-Restricted H-Y Antigen Contains a Posttranslationally Modified Cysteine That Significantly Affects T Cell Recognition. Immunity, 1997, 6, 273-281.	6.6	275
117	A Listeria monocytogenes Pentapeptide Is Presented to Cytolytic T Lymphocytes by the H2-M3 MHC Class Ib Molecule. Immunity, 1996, 5, 73-79.	6.6	109
118	Conservation of minor histocompatibility antigens between human and non-human primates. European Journal of Immunology, 1996, 26, 2680-2685.	1.6	16
119	Direct identification of tumor-associated peptide antigens. Seminars in Immunopathology, 1996, 18, 171-183.	4.0	8
120	Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. International Immunology, 1995, 7, 597-605.	1.8	77
121	Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science, 1995, 269, 1588-1590.	6.0	345
122	Structure of peptides associated with MHC class I molecules. Current Opinion in Immunology, 1994, 6, 13-23.	2.4	196
123	Direct analysis of tumor-associated peptide antigens. Current Opinion in Immunology, 1994, 6, 733-740.	2.4	58
124	Structure of Peptides Associated with Class I and Class II MHC Molecules. Annual Review of Immunology, 1994, 12, 181-207.	9.5	365
125	Mass Spectrometric Analysis of Peptides Associated with the Human Class I MHC Molecules HLA-A2.1 and HLA-B7 and Identification of Structural Features that Determine Binding. Chemical Immunology and Allergy, 1993, 57, 39-62.	1.7	17
126	Mass Spectrometric Analysis of Peptides Associated with the Human Class I MHC Molecules HLA-A2.1 and HLA-B7 and Identification of Structural Features that Determine Binding. Chemical Immunology and Allergy, 1993, 57, 39-62.	1.7	19

#	Article	IF	CITATIONS
127	Cell-cell adhesion mediated by CD8 and MHC class I molecules. Nature, 1988, 336, 79-81.	13.7	408
128	Immune Mechanisms Orchestrate Tertiary Lymphoid Structures in Tumors Via Cancer-Associated Fibroblasts. SSRN Electronic Journal, 0, , .	0.4	4